Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma
International Journal of Laboratory Hematology · 2025
DOI: 10.1111/ijlh.14366 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2025. Verfasst von Suwen Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Interferon Regulatory Factors, Plasma Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Medical and Health Science and Technology Program of Zhejiang Province.
Abstract (Originalsprache)
Introduction
Anti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.
Methods
Bone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.
Results
IRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples ( n = 10) with no PCs, the use of IRF‐4 enabled accurate nPC ( n = 12), aPC ( n = 13), and nPC + aPC ( n = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment ( n = 7; p = 0.610).
Conclusions
IRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, Zhejiang, China.
ORCID-Profile: Suwen Yang
Förderung
- Medical and Health Science and Technology Program of Zhejiang Province
Zitieren
APA
Yang, S., Hu, Q., Wang, X., Qiao, S., Qi, C., Jin, H., & Zhong, Y. (2025). Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14366
Vancouver
Yang S, Hu Q, Wang X, Qiao S, Qi C, Jin H, et al. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma. International Journal of Laboratory Hematology. 2025. doi:10.1111/ijlh.14366
BibTeX
@article{Yang2025,
author = {Yang, Suwen and Hu, Qianwen and Wang, Xiaofen and Qiao, Sai and Qi, Chao and Jin, Hong and Zhong, Yuhong},
title = {Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma},
journal = {International Journal of Laboratory Hematology},
year = {2025},
doi = {10.1111/ijlh.14366}
}
EUVIMED